Cellerix, a Spanish biopharma backed by venture capital investors, and Belgium-based TiGenix, have completed their merger by means of a share-for-share exchange.
This article is only available to subscribers to unquote.com. Subscribers just need to log in below for immediate access. Not a subscriber? Sign up now for immediate free trial access
Sign up
Free trial
Try unquote.com free for 2 weeks. A trial will give you access to the entire site.